{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T13:21:45Z","timestamp":1774099305123,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Carl Gustav Carus Dresden an der Technischen Universit\u00e4t Dresden"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Juvenile dermatomyositis (jDM) is the most common idiopathic inflammatory myopathy of childhood. Amyopathic or hypomyopathic courses have been described.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>We present the case of a 4-year-old patient with MDA5 antibody positive jDM and interstitial lung disease. In our patient, typical symptoms of jDM with classical skin lesions, arthritis, proximal muscle weakness, and ulcerative calcifications were observed. Due to the severity of the disease and the pulmonary changes, therapy with the Janus kinase (JAK) inhibitor ruxolitinib was added to the therapy with corticosteroids, intravenous immunoglobulins (IVIG) and hydroxychloroquine leading to a fast and sustained remission.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>While there is growing evidence that JAK inhibition is a promising therapeutic option in jDM our case report shows that this approach may also be effective in MDA5-positive jDM with high risk features.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12969-023-00894-9","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T08:03:50Z","timestamp":1695110630000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Rapid and sustained response to JAK inhibition in a child with severe MDA5\u2009+\u2009juvenile dermatomyositis"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9969-9517","authenticated-orcid":false,"given":"Timmy","family":"Strauss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Schnabel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Ae","family":"Lee-Kirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Normi","family":"Br\u00fcck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"issue":"02","key":"894_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1055\/a-1769-4299","volume":"47","author":"C Hinze","year":"2022","unstructured":"Hinze C, Dressler F, Schara-Schmidt U, Haas J-P. Juvenile dermatomyositis. Aktuelle Rheumatologie. 2022;47(02):99\u2013109.","journal-title":"Aktuelle Rheumatologie"},{"issue":"01","key":"894_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1055\/s-0037-1618163","volume":"33","author":"F Dressler","year":"2013","unstructured":"Dressler F, Thon A. Juvenile Dermatomyositis. Arthritis und Rheuma. 2013;33(01):25\u201332.","journal-title":"Arthritis und Rheuma"},{"key":"894_CR3","unstructured":"Cassidy JT, Petty RE, Laxer RM, Lindsley CB. Textbook of pediatric rheumatology E-Book. Elsevier Health Sciences; 2010."},{"key":"894_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/s11926-010-0101-6","volume":"12","author":"SA Greenberg","year":"2010","unstructured":"Greenberg SA. Dermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2010;12:198\u2013203.","journal-title":"Curr Rheumatol Rep"},{"key":"894_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10875-016-0359-1","volume":"37","author":"GI Rice","year":"2017","unstructured":"Rice GI, Melki I, Fr\u00e9mond M-L, Briggs TA, Rodero MP, Kitabayashi N, et al. Assessment of type I interferon signaling in pediatric inflammatory disease. J Clin Immunol. 2017;37:123\u201332.","journal-title":"J Clin Immunol"},{"issue":"2","key":"894_CR6","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1136\/annrheumdis-2016-209247","volume":"76","author":"FB Enders","year":"2017","unstructured":"Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329\u201340.","journal-title":"Ann Rheum Dis"},{"key":"894_CR7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.55563\/clinexprheumatol\/94btoy","volume":"40","author":"S Horn","year":"2022","unstructured":"Horn S, Minden K, Speth F, Schwarz T, Dressler F, Gr\u00f6sch N, et al. Paediatric rheumatology. Clin Exp Rheumatol. 2022;40:433\u201342.","journal-title":"Clin Exp Rheumatol"},{"key":"894_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11926-018-0798-1","volume":"20","author":"S Moghadam-Kia","year":"2018","unstructured":"Moghadam-Kia S, Oddis CV, Aggarwal R. Anti-MDA5 antibody spectrum in western world. Curr Rheumatol Rep. 2018;20:1\u20136.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"894_CR9","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/ng.2959","volume":"46","author":"JJ Miner","year":"2014","unstructured":"Miner JJ, Diamond MS. MDA5 and autoimmune disease. Nat Genet. 2014;46(5):418\u20139.","journal-title":"Nat Genet"},{"issue":"5","key":"894_CR10","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1517\/14656566.5.5.1083","volume":"5","author":"RD Sontheimer","year":"2004","unstructured":"Sontheimer RD. The management of dermatomyositis: current treatment options. Expert Opin Pharmacother. 2004;5(5):1083\u201399.","journal-title":"Expert Opin Pharmacother"},{"key":"894_CR11","doi-asserted-by":"crossref","unstructured":"McPherson M, Economidou S, Liampas A, Zis P, Parperis K, editors. Management of MDA-5 antibody positive clinically amyopathic dermatomyositis associated interstitial lung disease: a systematic review. Seminars in arthritis and Rheumatism. Elsevier; 2022.","DOI":"10.1016\/j.semarthrit.2022.151959"},{"key":"894_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-018-0257-6","volume":"16","author":"CH Hinze","year":"2018","unstructured":"Hinze CH, Oommen PT, Dressler F, Urban A, Weller-Heinemann F, Speth F, et al. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol. 2018;16:1\u20139.","journal-title":"Pediatr Rheumatol"},{"issue":"2","key":"894_CR13","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","volume":"62","author":"AM Huber","year":"2010","unstructured":"Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care & Research: Official Journal of the American College of Rheumatology. 2010;62(2):219\u201325.","journal-title":"Arthritis Care & Research: Official Journal of the American College of Rheumatology"},{"issue":"11","key":"894_CR14","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1093\/brain\/awz293","volume":"142","author":"S Sabbagh","year":"2019","unstructured":"Sabbagh S, Almeida de Jesus A, Hwang S, Kuehn HS, Kim H, Jung L, et al. Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. Brain. 2019;142(11):e59\u2013e.","journal-title":"Brain"},{"issue":"11","key":"894_CR15","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1093\/brain\/awy255","volume":"141","author":"FA Aeschlimann","year":"2018","unstructured":"Aeschlimann FA, Fr\u00e9mond M-L, Duffy D, Rice GI, Charuel J-L, Bondet V, et al. A child with severe juvenile dermatomyositis treated with ruxolitinib. Brain. 2018;141(11):e80\u2013e.","journal-title":"Brain"},{"issue":"3","key":"894_CR16","doi-asserted-by":"publisher","first-page":"e8","DOI":"10.1093\/brain\/awz005","volume":"142","author":"C Papadopoulou","year":"2019","unstructured":"Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D. Janus kinase 1\/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. Brain. 2019;142(3):e8\u2013e.","journal-title":"Brain"},{"issue":"9197","key":"894_CR17","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0140-6736(99)05157-0","volume":"355","author":"JP Callen","year":"2000","unstructured":"Callen JP, Dermatomyositis. The Lancet. 2000;355(9197):53\u20137.","journal-title":"The Lancet"},{"issue":"2","key":"894_CR18","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/rheumatology\/keaa436","volume":"60","author":"SE Sabbagh","year":"2021","unstructured":"Sabbagh SE, Neely J, Chow A, DeGuzman M, Lai J, Lvovich S, et al. Risk factors associated with pneumocystis jirovecii pneumonia in juvenile myositis in North America. Rheumatology. 2021;60(2):829\u201336.","journal-title":"Rheumatology"},{"issue":"6","key":"894_CR19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0022-3476(83)80706-9","volume":"103","author":"SL Bowyer","year":"1983","unstructured":"Bowyer SL, Blane CE, Sullivan DB, Cassidy JT. Childhood dermatomyositis: factors predicting functional outcome and development of dystrophic calcification. J Pediatr. 1983;103(6):882\u20138.","journal-title":"J Pediatr"},{"issue":"3","key":"894_CR20","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/S0889-857X(05)70350-1","volume":"23","author":"LG Rider","year":"1997","unstructured":"Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheumatic Disease Clinics of North America. 1997;23(3):619\u201355.","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"5","key":"894_CR21","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/S0031-3955(16)40054-4","volume":"42","author":"LM Pachman","year":"1995","unstructured":"Pachman LM. Juvenile dermatomyositis: pathophysiology and disease expression. Pediatr Clin North Am. 1995;42(5):1071\u201398.","journal-title":"Pediatr Clin North Am"},{"issue":"4","key":"894_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1067\/mjd.2002.122196","volume":"47","author":"RE Fisler","year":"2002","unstructured":"Fisler RE, Liang MG, Fuhlbrigge RC, Yalcindag A, Sundel RP. Aggressive management of juvenile dermatomyositis results in improved outcome and decreased incidence of calcinosis. J Am Acad Dermatol. 2002;47(4):505\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"894_CR23","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jaut.2019.03.003","volume":"100","author":"S Wendel","year":"2019","unstructured":"Wendel S, Venhoff N, Frye BC, May AM, Agarwal P, Rizzi M, et al. Successful treatment of extensive calcifications and acute pulmonary involvement in dermatomyositis with the Janus-Kinase inhibitor tofacitinib\u2013A report of two cases. J Autoimmun. 2019;100:131\u20136.","journal-title":"J Autoimmun"},{"issue":"3","key":"894_CR24","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1136\/annrheumdis-2020-218690","volume":"80","author":"H Kim","year":"2021","unstructured":"Kim H, Dill S, O\u2019Brien M, Vian L, Li X, Manukyan M, et al. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Ann Rheum Dis. 2021;80(3):406\u20138.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"894_CR25","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/rheumatology\/keaa558","volume":"60","author":"Z Yu","year":"2021","unstructured":"Yu Z, Wang L, Quan M, Zhang T, Song H. Successful management with Janus kinase inhibitor tofacitinib in refractory juvenile dermatomyositis: a pilot study and literature review. Rheumatology. 2021;60(4):1700\u20137.","journal-title":"Rheumatology"},{"key":"894_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-021-00637-8","volume":"19","author":"MG Ll Wilkinson","year":"2021","unstructured":"Ll Wilkinson MG, Deakin CT, Papadopoulou C, Eleftheriou D, Wedderburn LR. JAK inhibitors: a potential treatment for JDM in the context of the role of interferon-driven pathology. Pediatr Rheumatol. 2021;19:1\u201312.","journal-title":"Pediatr Rheumatol"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00894-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T01:31:53Z","timestamp":1703208713000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00894-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["894"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00894-9","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"6 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An ethics vote from Ethics Committee of Technical University Dresden was not required for this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient\u2019s parents gave their written consent to the publication of the case report and included patient photographs on Jan. 24, 2023.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}